Marchiafava–Bignami disease

From WikiMD's WELLNESSPEDIA

(Redirected from Marchiafava Bignami disease)

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC

Marchiafava–Bignami disease
Corpus callosum
Synonyms N/A
Pronounce N/A
Specialty N/A
Symptoms Dementia, seizures, dysarthria, coma
Complications Death
Onset Typically in middle-aged to elderly individuals
Duration Chronic
Types Type A (acute), Type B (chronic)
Causes Chronic alcoholism
Risks Alcohol use disorder
Diagnosis MRI, CT scan
Differential diagnosis Multiple sclerosis, Wernicke's encephalopathy, central pontine myelinolysis
Prevention N/A
Treatment Thiamine and other vitamin supplementation, abstinence from alcohol
Medication N/A
Prognosis Variable; can be fatal if untreated
Frequency Rare
Deaths N/A


Marchiafava–Bignami disease is a rare neurological disorder characterized by the degeneration of the corpus callosum, the thick band of nerve fibers that connects the two hemispheres of the brain. This disease is most commonly associated with chronic alcoholism and malnutrition, although it can also occur in individuals without a history of alcohol abuse.

Signs and Symptoms[edit]

The symptoms of Marchiafava–Bignami disease can vary widely but often include:

Pathophysiology[edit]

The exact cause of Marchiafava–Bignami disease is not well understood, but it is believed to be related to the toxic effects of alcohol and nutritional deficiencies, particularly of thiamine (vitamin B1). The disease leads to the demyelination and necrosis of the corpus callosum, which disrupts communication between the two hemispheres of the brain.

Diagnosis[edit]

Diagnosis is typically made through magnetic resonance imaging (MRI) or computed tomography (CT) scans, which can reveal lesions in the corpus callosum. Clinical history and neurological examination are also important for diagnosis.

Treatment[edit]

There is no specific treatment for Marchiafava–Bignami disease. Management focuses on addressing the underlying causes, such as alcohol cessation and nutritional support. Thiamine supplementation may be beneficial. Supportive care, including physical therapy and speech therapy, can help manage symptoms.

Prognosis[edit]

The prognosis for individuals with Marchiafava–Bignami disease varies. Some patients may recover partially or fully with appropriate treatment, while others may experience significant neurological deficits or death.

History[edit]

The disease was first described in 1903 by Italian pathologists Amico Bignami and Ettore Marchiafava, who observed the condition in chronic alcoholics.

See also[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.